



MEDIA RELEASE

QT VASCULAR PRODUCTS ARE PROMINENTLY FEATURED AT SCOTTSDALE INTERVENTIONAL FORUM

Highlights:

- **Live case features use of Chocolate® PTCA and Glider™ PTCA balloons**
- **Podium presentation features Chocolate's low trauma mechanism of action**

SINGAPORE, 18 March 2015 – QT Vascular Ltd., together with its subsidiaries (“**QT Vascular**” or the “**Group**”), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, is pleased to announce that it has successfully concluded a strong presence at the prestigious Scottsdale Interventional Forum (SIF) in Scottsdale, AZ.

Now in its 11th year, SIF utilizes a world-class faculty to provide attendees with the knowledge and skills to improve bedside management of complex coronary disease as well as apply the newest, most innovative technologies in cardiovascular medicine. Sessions include a review of adjunctive coronary imaging, coronary physiology, pharmacologic therapies, hemodynamic support and appropriateness criteria.

On the first live case transmission of the opening day of the conference, SIF course director, Dr. David Rizik (Scottsdale Healthcare Hospitals, Scottsdale, AZ) performed a highly complex intervention in a 42 year old male patient with severe cardiomyopathy and left ventricular assist device (LVAD) support. Using a Chocolate PTCA balloon (“Chocolate”), Dr. Rizik treated a left diagonal vessel. The parent vessel was then stented, which shifted plaque into the diagonal. Dr. Rizik then selected a Glider PTCA balloon (“Glider”) to cross through the side of the stent a back into the diagonal and then used a technique known as “kissing balloons” which yield an exceptional angiographic result. “In this highly complex patient, I was able to achieve “stent-like” results in this important side branch by using a combination of the Chocolate balloon for vessel preparation and the Glider for final inflation,” commented Dr. Rizik.

In addition to this live presentation, Chocolate was prominently featured in a presentation titled “Plaque Modification Therapies: Insights from OCT” by Dr. Sahil Parikh, Assistant Professor of Medicine at University Hospitals at Case Western Reserve in Cleveland, Ohio. Dr. Parikh elegantly explained Chocolate’s unique mechanism of action which leads to low vessel trauma and its potential advantages for use in calcium, lesions where use of drug-eluting stents may be “problematic”, as an ideal vessel preparation device or for use as a stand-alone treatment.

“From the exceptional interactions with physicians we had at our booth to the high quality scientific presentations on our products during the scientific sessions, we are delighted at the attention our technology commanded here in Scottsdale”, stated Dr. Eitan Konstantino, Ph.D., Chief Executive Officer of QT Vascular. “The SIF has become known as the premier west-coast conference in our industry. We are honoured to partner with such a group of renowned faculty and attendees.”

~~ End ~~

ABOUT QT VASCULAR LTD.

(SGX Stock code: 510, Bloomberg Code: QTVC SP, Reuters Code: QTVA.SI)

QT Vascular Ltd. together with its subsidiaries (“**QT Vascular**” or the “**Group**”) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, based in Pleasanton, California. Its vascular solution products include a range of percutaneous transluminal angioplasty (“**PTA**”) and percutaneous transluminal coronary angioplasty (“**PTCA**”) products.

With the exception of its direct sales of its coronary products (Chocolate[®] PTCA Balloon Catheter and Glider[™] PTCA Balloon Catheter) in the United States, these products are sold through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Johnson & Johnson), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

The Group is also applying for CE mark approval with respect to the Chocolate[®] Touch, its advanced drug-coated peripheral balloon.

For more information, please visit the company website at www.qtvvascular.com

Issued on behalf of **QT VASCULAR LTD.** by:

WATERBROOKS CONSULTANTS PTE LTD

Tel: +65 6100 2228

For media and analysts, please contact:

Mr Gary Ng	(T): +65 6430 0287	gng@trirememedical.com
Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg
Ms Angeline Cheong	(M): +65 9666 0977	angeline@waterbrooks.com.sg

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as “expect”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “plan”, “strategy”, “forecast” and similar expressions or future or conditional verbs such as “if”, “will”, “would”, “should”, “could”, “may” and “might”. These statements reflect the Company’s current

expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

QT Vascular Ltd. (the "Company") was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.